Efficacy and Safety of Cyclosporine Microemulsion in Diabetic Adult Stable Liver Transplant Recipients

Switch From Tacrolimus to Cyclosporine Microemulsion: Immunosuppressive Agents and Diabetes Management in Liver Transplant Recipients in Maintenance (DIALIVER)

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00171743

Enrollment

Registered

2005-09-15

Start date

2004-04-30

Completion date

2006-01-31

Last updated

2017-06-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplant

Keywords

Adults, Post transplant diabetes

Brief summary

The purpose of this study is to determine whether the switch from tacrolimus to cyclosporine microemulsion benefits post-transplant diabetes management (in terms of glycogenic control and insulin dosage) in stable liver transplant recipients.

Interventions

DRUGCyclosporine microemulsion

Study design

Allocation

NON_RANDOMIZED

Intervention model

FACTORIAL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* At least 4 months post-transplant * Patients in treatment with tacrolimus * Post-transplant diabetes treated with insulin for at least one month

Exclusion criteria

* Known hypersensitivity to cyclosporine microemulsion * Investigational drug within 60 days before baseline or during the study * Patients who cannot comply with the study requirements Other protocol-defined

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026